Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Preferred Stock Liabilities: 2013-2014

  • Coherus Oncology's Preferred Stock Liabilities was N/A to $161.2 million in Q3 2014 from the same period last year, while for Sep 2014 it was $161.2 million, marking a year-over-year change of. This contributed to the annual value of $54.7 million for FY2013, which is 993.90% up from last year.
  • Latest data reveals that Coherus Oncology reported Preferred Stock Liabilities of $161.2 million as of Q3 2014, which was up 194.66% from $54.7 million recorded in Q4 2013.
  • Coherus Oncology's Preferred Stock Liabilities' 5-year high stood at $161.2 million during Q3 2014, with a 5-year trough of $54.7 million in Q4 2013.
  • For the 2-year period, Coherus Oncology's Preferred Stock Liabilities averaged around $107.9 million, with its median value being $107.9 million (2013).